Common use of Drug Testing Methodology Clause in Contracts

Drug Testing Methodology. a. The testing or processing phase shall consist of: (i) Initial screening test; (ii) Confirmation test-if the initial screen testing is positive. b. The urine sample is first tested using the initial drug screening procedure. An initial positive test result will not be considered conclusive; rather, it will be classified as “confirmation pending.” Notification of test results to the supervisor or other departmental designee shall be held until the confirmation test results are obtained and verified by the MRO. c. A specimen testing positive will undergo an additional confirmatory test. The confirmation procedure shall be technologically different and more sensitive than the initial screening test. d. The drug screening tests selected shall be capable of identifying marijuana, cocaine and every major drug of abuse, including heroin, amphetamines and barbiturates. Personnel utilized for testing will be qualified to collect urine samples, or adequately trained in collection procedures. e. Concentrations of a drug at or about the following levels shall be considered a positive test result when using the initial immunoassay drug screening test: (i) Initial Test Standards. The initial test shall use an immunoassay which meets the requirements of the Food and Drug Administration for commercial distribution. The following initial cutoff levels shall be used when screening specimens to determine whether negative or positive for these classes of drugs: SKBL Analyte Initial Test Level (ng/ml) Marijuana 50 ng/ml Cocaine 300 ng/ml Opiates 2000 ng/ml Phencyclidine 25 ng/ml Amphetamine 1000 ng/ml Some specimens may be subjected to initial testing by methods other than immunoassays, where the latter are unavailable for detection of specific drugs of special concern. (ii) Confirmatory Test Standards. All specimens identified as positive on the initial screening test shall be confirmed using gas chromatography/mass spectrometry (GC/MS) techniques and by quantitative analysis at the cutoff levels listed below: SKBL Analyte Initial Test Level (ng/ml)_ Marijuana 15 ng/ml Cocaine 150 ng/ml Opiates: Morphine 2000 ng/ml Codeine 2000 ng/ml Phencyclidine 5 ng/ml Amphetamine 500 ng/ml

Drug Testing Methodology. a. (a) The testing or processing phase shall consist ofof a two-step procedure: (i) 1. Initial screening test; 2. Confirmation test (iib) Confirmation test-if the initial screen testing is positive. b. The urine sample is first tested using the initial drug screening procedure. An initial positive test result will not be considered conclusive; rather, it will be classified as “confirmation pending.” Notification of test results to the supervisor or other departmental designee shall be held until the confirmation test results are obtained and verified by the MROobtained. c. (c) A specimen testing positive will undergo an additional confirmatory test. The confirmation procedure shall be technologically different and more sensitive than the initial screening test. d. (d) The drug screening tests selected shall be capable of identifying marijuana, cocaine and every major drug of abuse, abuse including heroin, amphetamines and barbiturates. Personnel utilized for testing will be certified as qualified to collect urine samples, samples or adequately trained in collection procedures. e. (e) Concentrations of a drug at or about above the following levels shall be considered a positive test result when using the initial a FPIA immunoassay drug screening test: . Amphetamines 500 ng/1 Barbiturates 500 ng/1 Cocaine 300 ng/1 Opiates 300 ng/1 THC 100 ng/1 PCP 25 ng/1 Benzodiazepines 200 ng/1 Methadone 25 ng/1 (if) Initial Test Standards. The initial test shall use an immunoassay which meets Concentrations of a drug at or above the requirements of the Food and Drug Administration for commercial distribution. The following initial cutoff levels shall be used considered a positive test result when screening specimens to determine whether negative or performing a confirmatory GC/MS test on a urine specimen that tested positive for these classes of drugs: SKBL Analyte Initial Test Level (ng/ml) Marijuana 50 ng/ml Cocaine 300 ng/ml Opiates 2000 ng/ml Phencyclidine 25 ng/ml Amphetamine 1000 ng/ml Some specimens may be subjected to initial testing by methods other than immunoassays, where the latter are unavailable for detection of specific drugs of special concern. (ii) Confirmatory Test Standards. All specimens identified as positive on the using a technologically different initial screening test shall be confirmed using gas chromatography/mass spectrometry (GC/MS) techniques and by quantitative analysis at the cutoff levels listed below: SKBL Analyte Initial Test Level (ng/ml)_ method. Marijuana 15 ng/ml metabolite 15* Cocaine 150 ng/ml metabolite 150** Opiates: Morphine 2000 ng300** Codeine 300*** Phencyclidine 25 Amphetamines: Amphetamine 500 Methamphetamine 500 * Delta-9 tetrahydrocannabinol-9-carboxylic acid ** Benzoylecgonine *** 25ng/ml Codeine 2000 ng/ml Phencyclidine 5 ng/ml Amphetamine 500 ng/mlif immunoassay-specific for free morphine

Drug Testing Methodology. a. A. The testing or processing phase shall consist ofof a two-step procedure: (i) 1. Initial screening test; (ii) 2. Confirmation test-if the initial screen testing is positive. b. B. The urine sample is first tested using the initial drug screening procedureprocedure of the RIA and/or EMIT type. An initial positive test result will not be considered conclusive; rather, it will be classified as “"confirmation pending.” ". Notification of test results to the supervisor or other departmental designee shall be held until the confirmation test results are obtained and verified by the MRO.M.R.O. c. C. A specimen specimen-testing positive will undergo an additional confirmatory test. The confirmation procedure shall be technologically different and more sensitive than of the initial screening testgas chromatography/mass spectrometry method. d. D. The drug screening tests selected shall be capable of identifying marijuana, cocaine and every major drug of abuse, abuse including heroin, phencyclidine, amphetamines and barbiturates. Personnel utilized for testing will be certified as qualified to collect urine samples, sample or adequately trained in collection procedures. e. E. Concentrations of a drug at or about a minimum of the following levels shall be considered a positive test result when using the initial immunoassay drug drug- screening test: (i) Initial Test Standards: Marijuana metabolite 100 Cocaine metabolite 300 Opiate metabolites 300* Phencyclidine 25 Amphetamines 1000 Barbiturate 300 * 25ng/ml if immunoassay specific for free morphine. The initial test shall use an immunoassay which meets Concentrations of a drug at or above the requirements of the Food and Drug Administration for commercial distribution. The following initial cutoff levels shall be used considered a positive test result when performing a confirmatory CG/MS test on a urine specimen that tested positive using a technologically different test than the initial screening specimens to determine whether negative or positive for these classes of drugsmethod: SKBL Analyte Initial Confirmatory Test Level (ng/ml) Marijuana 50 ngmetabolite 15* Morphine 300+ Codeine 300+ Phencyclidine 25 Cocaine metabolite 150** Opiates: Amphetamines: Amphetamine 500 Methamphetamine 500 *Delta-9 tetrahydrocannabinol -9- carboxylic acid **Benzoylecgonine + 25ng/ml Cocaine 300 ng/ml Opiates 2000 ng/ml Phencyclidine 25 ng/ml Amphetamine 1000 ng/ml Some specimens may if immunoassay -specific for free morphine Barbiturates 300 F. The Union will be subjected to initial testing notified of any changes in cutoff levels that are set in accordance with levels determined by methods other than immunoassays, where the latter are unavailable for detection of specific drugs of special concernMichigan Law Enforcement Officers Training Council. (ii) Confirmatory Test Standards. All specimens identified as positive on G. The laboratory selected to conduct the initial screening test analysis shall be confirmed using gas chromatography/mass spectrometry (GC/MS) techniques experienced and by quantitative analysis at capable of quality control, documentation, chain of custody, technical expertise and demonstrated proficiency in urinalysis. H. Employees having negative drug test results shall receive a memorandum stating that no illegal drugs were found. A copy of the cutoff levels listed below: SKBL Analyte Initial Test Level (ng/ml)_ Marijuana 15 ng/ml Cocaine 150 ng/ml Opiates: Morphine 2000 ng/ml Codeine 2000 ng/ml Phencyclidine 5 ng/ml Amphetamine 500 ng/mlletter will be placed in the employee's personnel file. I. Any employee who interferes with the testing process or breaches the confidentiality of test results shall be subject to discipline.

Drug Testing Methodology. a. 1. The testing or processing phase shall consist ofof a two-step procedure: (i) a. Initial screening test;, and (ii) b. Confirmation test-if the initial screen testing is positive. b. 2. The urine sample is first tested using the initial drug screening procedure. An initial positive test result will not be considered conclusive; rather, it will be classified as “confirmation pending.” Notification of test results to the supervisor or other departmental designee shall be held until the confirmation test results are obtained and verified by the MROobtained. c. 3. A specimen specimen-testing positive will undergo an additional confirmatory test. The confirmation procedure shall be technologically different and more sensitive than the initial screening test. d. 4. The drug screening tests selected shall be capable of identifying marijuana, cocaine cocaine, and every major drug of abuse, abuse including heroin, amphetamines amphetamine and barbiturates. Personnel utilized for testing will be certified as qualified to collect urine samples, samples or adequately trained in collection procedures. e. 5. Concentrations of a drug at or about above the following levels shall be considered a positive test result when using the initial immunoassay drug screening test: (i) Initial Test Standards. The initial test shall use an : Marijuana metabolite 100 Cocaine metabolite 300 Opiate metabolites 3001 Phencyclidine 25 Amphetamines 1000 125ng/ml if immunoassay which meets specific for free morphine Concentrations of a drug at or above the requirements of the Food and Drug Administration for commercial distribution. The following initial cutoff levels shall be used considered a positive test result when screening specimens to determine whether negative or performing a confirmatory GC/MS Xxxx on a urine specimen that tested positive for these classes of drugs: SKBL Analyte Initial Test Level (ng/ml) Marijuana 50 ng/ml Cocaine 300 ng/ml Opiates 2000 ng/ml Phencyclidine 25 ng/ml Amphetamine 1000 ng/ml Some specimens may be subjected to initial testing by methods other than immunoassays, where the latter are unavailable for detection of specific drugs of special concern. (ii) Confirmatory Test Standards. All specimens identified as positive on the using a technologically different initial screening test shall be confirmed using gas chromatography/mass spectrometry (GC/MS) techniques and by quantitative analysis at the cutoff levels listed below: SKBL Analyte Initial Test Level (ng/ml)_ method Marijuana 15 ng/ml metabolite 152 Cocaine 150 ng/ml metabolite 1503 Opiates: Morphine 2000 ng/ml *300 Codeine 2000 ng/ml *300 Phencyclidine 5 ng/ml 25 Amphetamines: Amphetamine 500 ng/mlMethamphetamine 500 2 Delta-9-tetrahydrocannabino1-9-carboxylic acid 3 Benzoylecgonine 6. The laboratory selected to conduct the analysis shall be experienced and capable of quality control, documentation, chain-of-custody, technical expertise, and demonstrated proficiency in urinalysis. 7. Employees having negative drug test results shall receive a memorandum stating that no illegal drugs were found. If the employee requests such, a copy of the letter will be placed in the employee’s personnel file. 8. Any employee who breaches the confidentiality of testing information shall be subject to discipline.

Drug Testing Methodology. a. a) The testing or processing phase shall consist ofof a two-step procedure: (i) 1. Initial screening test; (ii) 2. Confirmation test-if the initial screen testing is positive. b. b) The urine sample is first tested using the initial drug screening procedureprocedure of the RIA and/or EMITS type. An initial positive test result will not be considered conclusive; rather, it will be classified as “"confirmation pending.” " Notification of test results to the supervisor or other departmental designee shall be held until the confirmation test results are obtained and verified by the MRO.M.R.O. c. c) A specimen testing positive will undergo an additional confirmatory confirmation test. The confirmation procedure shall be technologically different and more sensitive than of the initial screening testgas chromatography/mass spectrometry method. d. d) The drug screening tests selected shall be capable of identifying marijuana, cocaine and every major drug of abuse, abuse including heroin, phencyclidine, amphetamines and barbiturates. Personnel utilized for testing will be certified as qualified to collect urine samples, sample or adequately trained in collection procedures. e. e) Concentrations of a drug at or about a minimum of the following levels shall be considered a positive test result when using the initial immunoassay drug drug-screening test: (i) Initial Test Standards. The initial test shall use an immunoassay which meets the requirements of the Food and Drug Administration for commercial distribution. The following initial cutoff levels shall be used when screening specimens to determine whether negative or positive for these classes of drugs: SKBL Analyte Initial Test Level (ng/ml) Marijuana 50 ng*25ng/ml Cocaine 300 ng/ml Opiates 2000 ng/ml Phencyclidine 25 ng/ml Amphetamine 1000 ng/ml Some specimens may be subjected to initial testing by methods other than immunoassays, where the latter are unavailable if immunoassay specific for detection of specific drugs of special concern. (ii) Confirmatory Test Standardsfree morphine. All specimens identified as positive on the initial screening test shall be confirmed using gas chromatography/mass spectrometry (GC/MS) techniques and by quantitative analysis at the cutoff levels listed below: SKBL Analyte Initial Confirmation Test Level (ngnag/ml)_ Marijuana 15 ng) Opiates: Amphetamines: *Delta - 9 tetrahydrocannabinol -9- carboxylic acid *25ng/ml Cocaine 150 ng/ml Opiates: Morphine 2000 ng/ml Codeine 2000 ng/ml Phencyclidine 5 ng/ml Amphetamine 500 ng/mlif immunoassay -specific for free morphine The Association will be notified of any changes in cutoff levels. f) The laboratory selected to conduct the analysis shall be experienced and capable of quality control, documentation, chain of custody, technical expertise and demonstrated proficiency in urinalysis. g) Employees having negative drug test results shall receive a memorandum stating that no illegal drugs were found. A copy of the letter will be placed in the employee's personnel file upon the employee's request. h) Any employee who interferes with the testing process or breaches the confidentiality of test results shall be subject to discipline.

Drug Testing Methodology. a. A. The testing or processing phase shall consist ofof a two-step procedure: (i) 1. Initial screening test;; and (ii) 2. Confirmation test-if the initial screen testing is positive. b. B. The urine laboratory conducting the analysis shall be experienced and capable of quality control, documentation, chain of custody, technical expertise, and demonstrated proficiency in urinalysis. C. All drug testing performed under this policy shall be performed by a professionally qualified laboratory meeting standards defined by local, state, or federal authorities and approved by this agency. D. The urine, blood or breath sample is first tested using the initial drug screening procedure. An initial positive test result will not be considered conclusive; rather, it will be classified as “"confirmation pending.” " Notification of test results to the supervisor Chief or other departmental his designee shall be held until the confirmation test results are obtained and verified by the MROobtained. c. E. A specimen testing positive will undergo an additional confirmatory test. The confirmation procedure shall be technologically different and more sensitive than the initial screening test. d. F. The drug screening tests test selected shall be capable of identifying marijuana, cocaine cocaine, and every major drug of abuse, including heroin, amphetamines amphetamines, and barbiturates. Personnel utilized for testing will be certified as qualified to collect urine samplesurine, blood or breath samples or adequately trained in collection procedures. e. G. Concentrations of a drug the listed drugs at or about above the following levels shall be considered a positive test result when using the initial fluorescence polarization immunoassay analysis drug screening test: (i) : Initial Test Standards. The initial test shall use an immunoassay which meets the requirements of the Food and Drug Administration for commercial distribution. The following initial cutoff levels shall be used when screening specimens to determine whether negative or positive for these classes of drugs: SKBL Analyte Initial Test Cutoff Levels in nanogram/milliliter (ng/ml) Level (ng/ml) Marijuana 50 ng/ml Cocaine 300 ng/ml Opiates Opiate metabolites 2000 ng/ml Phencyclidine 25 ng/ml Amphetamine Amphetamines 1000 ng/ml Some specimens may be subjected Notwithstanding the foregoing, the listing of only certain controlled substances does not preclude the Department from determining the concentrations of other, unlisted controlled substances to initial testing by methods other than immunoassays, where the latter are unavailable for detection of specific drugs of special concernconstitute a positive drug test. (ii) Confirmatory Test Standards. All specimens identified as positive on H. Concentrations of the initial screening test following drugs at or above the following levels shall be confirmed using considered a positive test result when performing a confirmatory gas chromatography/mass spectrometry spectrophotometry (GC/MS) techniques and by quantitative analysis at the cutoff levels listed belowtest on a urine specimen that tested positive using a technologically different initial screening method: SKBL Analyte Initial Confirmatory Test Cutoff Levels in nanogram/milliliter (ng/ml)* Level (ng/ml)_ ) Marijuana metabolite (1) 15 ng/ml Cocaine metabolite (2) 150 ng/ml Opiates: Morphine 2000 ng/ml Codeine 2000 ng/ml 6-Acetyl morphine (3) 10 Phencyclidine 5 ng/ml Amphetamine 25 Amphetamines: Amphetamines 500 ng/mlMethamphetamine (4) 500 (1) Delta-9-tetrahydrocannabinol-9-carboxylic acid

Drug Testing Methodology. a. A. The testing or processing phase shall consist ofof a two-step procedure: (i) 1. Initial screening test;; and (ii) 2. Confirmation test-if the initial screen testing is positive. b. B. The urine laboratory conducting the analysis shall be experienced and capable of quality control, documentation, chain of custody, technical expertise, and demonstrated proficiency in urinalysis. C. All drug testing performed under this policy shall be performed by a professionally qualified laboratory meeting standards defined by local, state, or federal authorities and approved by this agency. D. The urine, blood or breath sample is first tested using the initial drug screening procedure. An initial positive test result will not be considered conclusive; rather, it will be classified as “"confirmation pending.” " Notification of test results to the supervisor Chief or other departmental his designee shall be held until the confirmation test results are obtained and verified by the MROobtained. c. E. A specimen testing positive will undergo an additional confirmatory test. The confirmation procedure shall be technologically different and more sensitive than the initial screening test. d. F. The drug screening tests test selected shall be capable of identifying marijuana, cocaine cocaine, and every major drug of abuse, including heroin, amphetamines amphetamines, and barbiturates. Personnel utilized for testing will be certified as qualified to collect urine samplesurine, blood or breath samples or adequately trained in collection procedures. e. G. Concentrations of a drug the listed drugs at or about above the following levels shall be considered a positive test result when using the initial fluorescence polarization immunoassay analysis drug screening test: (i) : Initial Test Standards. The initial test shall use an immunoassay which meets the requirements of the Food and Drug Administration for commercial distribution. The following initial cutoff levels shall be used when screening specimens to determine whether negative or positive for these classes of drugs: SKBL Analyte Initial Test Cutoff Levels in nanogram/milliliter (ng/ml) Level (ng/ml) Marijuana 50 ng/ml Cocaine 300 ng/ml Opiates Opiate metabolites 2000 ng/ml Phencyclidine 25 ng/ml Amphetamine Amphetamines 1000 ng/ml Some specimens may be subjected Notwithstanding the foregoing, the listing of only certain controlled substances does not preclude the Department from determining the concentrations of other, unlisted controlled substances to initial testing by methods other than immunoassays, where the latter are unavailable for detection of specific drugs of special concernconstitute a positive drug test. (ii) Confirmatory Test Standards. All specimens identified as positive on H. Concentrations of the initial screening test following drugs at or above the following levels shall be confirmed using considered a positive test result when performing a confirmatory gas chromatography/mass spectrometry spectrophotometry (GC/MS) techniques and by quantitative analysis at the cutoff levels listed belowtest on a urine specimen that tested positive using a technologically different initial screening method: SKBL Analyte Initial Confirmatory Test Cutoff Levels in nanogram/milliliter (ng/ml)* Level (ng/ml)_ ) Marijuana metabolite (1) 15 ng/ml Cocaine metabolite (2) 150 ng/ml Opiates: Morphine 2000 ng/ml Codeine 2000 ng/ml 6-Acetyl morphine (3) 10 Phencyclidine 5 ng/ml Amphetamine 25 Amphetamines: Amphetamines 000 Xxxxxxxxxxxxxxx (4) 500 ng/ml(1) Delta-9-tetrahydrocannabinol-9-carboxylic acid

Drug Testing Methodology. a. 1. The testing or processing phase shall consist of: (i) a. Initial screening test;. (ii) b. Confirmation test---if the initial screen testing screening test is positive. b. 2. The urine sample is first tested using the initial drug screening procedure. An initial positive test result will not be considered 0, conclusive; rather, it will be classified as “"confirmation pending.” " Notification of test results to the supervisor or other departmental designee shall be held until the confirmation test results are obtained and verified by the MRO. c. 3. A specimen testing positive will undergo an additional confirmatory test. The , the confirmation procedure shall be technologically different and more sensitive than the initial screening test. d. 4. The drug screening tests selected shall be capable of identifying marijuana," cocaine, cocaine and every major drug of abuse, abuse including heroin, amphetamines and barbiturates. Personnel utilized for testing will be qualified to collect urine samples, or adequately trained in collection procedures. e. 5. Concentrations of a drug at or about the following levels shall be be. considered a positive test result when using the initial immunoassay drug screening test: (i) Initial Test Standards. The initial test shall use an immunoassay which meets the requirements of the Food and Drug Administration for commercial distribution. The following initial cutoff levels shall be used when screening specimens to determine whether negative or positive for these classes of drugs: SKBL Analyte Initial Test Level (ng/ml) Marijuana 50 ng/ml metabolite 100 Cocaine metabolite 300 ng/ml Opiates 2000 ng/ml Opiate Metabolite 300* Phencyclidine 25 ngAmphetamines 1000 Barbiturates 300 Concentrations of a drug at or above the following levels shall be considered a positive test result when performing a confirmatory CG/ml Amphetamine 1000 ng/ml Some specimens may be subjected to initial testing by methods other MS test on a urine specimen that tested positive using a technologically different test than immunoassays, where the latter are unavailable for detection of specific drugs of special concern. (ii) Confirmatory Test Standards. All specimens identified as positive on the initial screening test shall be confirmed using gas chromatography/mass spectrometry (GC/MS) techniques and by quantitative analysis at the cutoff levels listed below: SKBL Analyte Initial Test Level (ng/ml)_ method. Marijuana Metabolite 15 ng/ml * Cocaine metabolite 150 ng/ml * * Opiates: Morphine 2000 ng300 + Codeine 300 + Phencyclidine Amphetamines: 25 Amphetamine 500 Methamphetamine 500 Barbiturates 300 * Delta-8-tetrahydrocannabinol-0-carboxylic acid. * * Benzoylecgonine. + 25ng/ml Codeine 2000 ng/ml Phencyclidine 5 ng/ml Amphetamine 500 ng/mlif immunoassay-specific for free morphine. 6. The initial and confirmatory test cut off levels of this order are the same as that of the United States Government which were published in the Federal Register, Volume 54, Number 230, dated December 1, 1989. 7. The laboratory selected to conduct the analysis shall be experienced and capable of assuring quality control, documentation, chain of custody, technical expertise and demonstrated proficiency in urinalysis. 8. Employees having negative drug test results shall receive a memorandum stating that no illegal drugs were found. A copy of the letter will be placed in the employee’s personnel file upon the employee’s request. 9. Any employee who interferes with the testing process or breaches the confidentiality of test results shall be subject to discipline.

Drug Testing Methodology. a. The testing or processing phase shall consist of: (i) Initial screening test; (ii) Confirmation test-if the initial screen testing is positive. b. The urine sample is first tested using the initial drug screening procedure. An initial positive test result will not be considered conclusive; rather, it will be classified as “confirmation pending.” Notification of test results to the supervisor or other departmental designee shall be held until the confirmation test results are obtained and verified by the MRO. c. A specimen testing positive will undergo an additional confirmatory test. The confirmation procedure shall be technologically different and more sensitive than the initial screening test. d. The drug screening tests selected shall be capable of identifying marijuana, cocaine and every major drug of abuse, including heroin, amphetamines and barbiturates. Personnel utilized for testing will be qualified to collect urine samples, or adequately trained in collection procedures. e. Concentrations of a drug at or about the following levels shall be considered a positive test result when using the initial immunoassay drug screening test: (i) Initial Test Standards. The initial test shall use an immunoassay which meets the requirements of the Food and Drug Administration for commercial distribution. The following initial cutoff levels shall be used when screening specimens to determine whether negative or positive for these classes of drugs: SKBL Analyte Initial Test Level (ng/ml) Marijuana 50 ng/ml Cocaine 300 ng/ml Opiates 2000 ng/ml Phencyclidine 25 ng/ml Amphetamine 1000 ng/ml Some specimens may be subjected to initial testing by methods other than immunoassays, where the latter are unavailable for detection of specific drugs of special concern. (ii) Confirmatory Test Standards. All specimens identified as positive on the initial screening test shall be confirmed using gas chromatography/mass spectrometry (GC/MS) techniques and by quantitative analysis at the cutoff levels listed below: SKBL Analyte Initial Test Level (ng/ml)_ Marijuana 15 ng/ml Cocaine 150 ng/ml Opiates: Morphine 2000 ng/ml Codeine 2000 ng/ml Phencyclidine 5 ng/ml Amphetamine 500 ng/ml

Drug Testing Methodology. a. 1. The testing or processing phase shall consist of: (i) Initial a. initial screening test; (ii) Confirmation test-b. confirmation test -- if the initial screen testing screening test is positive. b. 2. The urine sample is first tested using the initial drug screening procedure. An initial positive test result will not be considered conclusive; rather, it will be classified as “"confirmation pending.” " Notification of test results to the supervisor or other departmental designee shall be held until the confirmation test results are obtained and verified by the MRO.M.R.O. c. 3. A specimen testing positive will undergo an additional confirmatory test. The confirmation procedure shall be technologically different and more sensitive than the initial screening test. d. 4. The drug screening tests selected shall be capable of identifying marijuana, cocaine and every major drug of abuse, abuse including heroin, phencyclidine, amphetamines and barbiturates. Personnel utilized for testing will be qualified to collect urine samples, or adequately trained in collection procedures. e. 5. Concentrations of a drug at or about the following levels shall be considered a positive test result when using the initial immunoassay drug screening test: (i) : Initial Test StandardsLevel Marijuana metabolite 100 Cocaine metabolite. The initial test shall use an immunoassay which meets 300 Opiate metabolite 300* Phencyclidine 25 Amphetamines 1000 Barbiturates 300 *25ng/ml if immunoassay-specific for free morphine. Concentrations of a drug at or above the requirements of the Food and Drug Administration for commercial distribution. The following initial cutoff levels shall be used considered a positive test result when performing a confirmatory CG/MS test on a urine specimen that tested positive using a technologically different test than the initial screening specimens to determine whether negative or positive for these classes of drugsmethod: SKBL Analyte Initial (ng/ml) Confirmatory Test Level (ng/ml) Marijuana 50 ng/ml metabolite 15* Cocaine 300 ng/ml Opiates 2000 ng/ml Phencyclidine 25 ng/ml Amphetamine 1000 ng/ml Some specimens may be subjected to initial testing by methods other than immunoassays, where the latter are unavailable for detection of specific drugs of special concern. (ii) Confirmatory Test Standards. All specimens identified as positive on the initial screening test shall be confirmed using gas chromatography/mass spectrometry (GC/MS) techniques and by quantitative analysis at the cutoff levels listed below: SKBL Analyte Initial Test Level (ng/ml)_ Marijuana 15 ng/ml Cocaine 150 ng/ml metabolite 150** Opiates: Morphine 2000 ng300+ Codeine 300+ Phencyclidine 25 Amphetamines: Amphetamine 500 Methamphetamine 500 * Delta-9-tetrahydrocannabinol-9-carboxylic acid ** Benzoylecgonine + 25ng/ml Codeine 2000 ng/ml Phencyclidine 5 ng/ml Amphetamine 500 ng/mlif immunoassay-specific for free morphine Barbiturates 300 6. The initial and confirmatory test cutoff levels of this order are the same as that of the United States government which were published in the Federal Register, volume 54, number 230, dated December 1, 1989. These cutoff levels are subject to change by the Department of Health and Human Services as advances in technology or other considerations warrant identification of these substances at other concentrations. If these cutoff levels change in the future, the matter will be discussed with the labor associations prior to any amendment of this general order. 7. The laboratory selected to conduct the analysis shall be experienced and capable of assuring quality control, documentation, chain-of-custody, technical expertise and demonstrated proficiency in urinalysis. 8. Dispatchers having negative drug test results shall receive a memorandum stating that no illegal drugs were found. A copy of the letter will be placed in the Dispatcher's personnel file upon the Dispatcher's request. 9. Any Dispatcher who interferes with the testing process or breaches the confidentiality of test results shall be subject to discipline.

Drug Testing Methodology. a. 1. The testing or processing phase shall consist ofof a two-step procedure: (i) a. Initial screening test; (ii) b. Confirmation test-if the initial screen testing is positive. b. 2. The urine sample is first tested using the initial drug screening procedure. An initial positive test result will not be considered conclusive; rather, it will be classified as “"confirmation pending.” ". Notification of test results to the supervisor or other departmental designee shall be held until the confirmation Confirmation test results are obtained and verified by the MROobtained. c. 3. A specimen testing positive will undergo an additional confirmatory test. The confirmation procedure shall be technologically different and more sensitive than the initial screening test. d. 4. The drug screening tests selected shall be capable of identifying marijuana, cocaine and every major drug of abuse, abuse including heroin, amphetamines and barbiturates. Personnel utilized for testing will be certified as qualified to collect urine samples, samples or adequately trained in collection procedures. e. 5. Concentrations of a drug at or about above the following levels shall be considered a positive test result when using the initial a FPIA immunoassay drug screening test: (i) Initial Test Standards. The initial test shall use an immunoassay which meets : Amphetamines 1000 ng/1 Barbiturates 500 ng/1 Cocaine 300 ng/1 Opiates 300 ng/1 THC 100 ng/1 PCP 25 ng/1 Benzodiazepines 300 ng/1 Methadone 25 ng/1 Concentration of a drug at or above the requirements of the Food and Drug Administration for commercial distribution. The following initial cutoff levels shall be used considered a positive test result when screening specimens to determine whether negative or performing a confirmatory GC/MS test on a urine specimen that tested positive for these classes of drugs: SKBL Analyte Initial Test Level (ng/ml) Marijuana 50 ng/ml Cocaine 300 ng/ml Opiates 2000 ng/ml Phencyclidine 25 ng/ml Amphetamine 1000 ng/ml Some specimens may be subjected to initial testing by methods other than immunoassays, where the latter are unavailable for detection of specific drugs of special concern. (ii) Confirmatory Test Standards. All specimens identified as positive on the using a technologically different initial screening test shall be confirmed using gas chromatography/mass spectrometry (GC/MS) techniques and by quantitative analysis at the cutoff levels listed below: SKBL Analyte Initial Test Level (ng/ml)_ method. Marijuana metabolite 15 ng/ml * Cocaine metabolite 150 ng/ml ** Opiates: Morphine 2000 ng300 *** Codeine 300 Phencyclidine 25 Amphetamines: Amphetamine 500 Methamphetamine 500 * Delta-9 tetrahydrocannabinol-9-carboxylic acid ** Benzoylecgonine *** 25ng/ml Codeine 2000 ng/ml Phencyclidine 5 ng/ml Amphetamine 500 ng/mlif immunoassay-specific for free morphine 6. The laboratory selected to conduct the analysis shall be experienced and capable of quality control, documentation, chain-of-custody, technical expertise, and demonstrated proficiency in urinalysis. 7. Employees having negative drug test results shall receive a memorandum stating that no illegal drugs were found. If the employee requests such, a copy of the letter will be placed in theemployee's personnel file.